No chance to move forward. Why do you bozos call this the phase 3 issue? Repros not even close to finishing phase 2 as usual. Same story over and over. Joey left this mismanaged company in disarray after he plundered its cash reserves over years of incompetence. Same "Type C" discussions citing issues that Joey continuously overlooked. "Shortly before the meeting, the Company was notified that the meeting would be a type C/Guidance meeting, rather than a type B/End of phase 2 meeting as previously anticipated. At the meeting, the FDA confirmed that Proellex® will continue on the current partial clinical hold while they consult with liver experts within the FDA regarding previously disclosed effects on the liver. Further, the FDA agreed to accept additional information from the Company and its panel of liver experts for consideration by the FDA’s internal advisory liver team. The Company expects to submit the additional information and a proposed clinical protocol within a month. The Company intends to announce further information following receipt of additional guidance from the FDA."
IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!
2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL
MarketCap $50 Million Cash ~$12 Million (including convertible debt) =cash untill 2021+ Price: 0.80
NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July NDA resubmission for Rizaport (migraine) in early Q3 Partnership for Tadalafil in 2H 2017
IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.
Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.
IntelGenx has multi-faceted BD approach for its oral films
With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
what is going on? any news on FDA hold???
This stock has been a complete loser for me. Will it ever make it back?
Massive short squeeze set up, imo shorts just shorted an additional 1.5M shares i've been counting short sales alll day and with any positive news on FDA decision to move Proellex into a phase 3 which i expect...the competing Abbvie fibroid product not as effective sells $2.8B a year, this could be the mother of all short squeezes..... and shorts are caught between a rock and a hard place...instead of covering and running this over $1. and getting out of harms's way..they would instead prefer to get slaughtered, imo....mark this post!!
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On June 14, 2017, Repros Therapeutics Inc. (the “Company”) received a notification letter (the “Notice”) from NASDAQ advising the Company that for 30 consecutive business days preceding the date of the Notice, the closing bid price of the Company’s common stock had been below the $1.00 per share minimum required for continued listing on The NASDAQ Capital Market pursuant to NASDAQ Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Rule”).
The Notice has no effect on the listing of the Company’s common stock at this time and the Company’s common stock will continue to trade on the NASDAQ Capital Market under the symbol “RPRX.”
The Notice also stated that the Company will be provided 180 calendar days, or until December 11, 2017, to regain compliance with the Minimum Bid Price Rule. To do so, the closing bid price of the Company’s common stock must be at or above $1.00 per share for a minimum of ten consecutive business days prior to that date.
If by December 11, 2017 the Company cannot demonstrate compliance with the Minimum Bid Price Rule, the Company may be eligible for additional time. To qualify, the NASDAQ staff will determine whether or not the Company meets The NASDAQ Capital Market initial listing criteria set forth in NASDAQ Marketplace Rule 5550, except for the Minimum Bid Price Rule. If the Company meets the initial listing criteria (with the exception of the Minimum Bid Price Rule) and provides written notice of its intention to cure the deficiency during the second compliance period, the NASDAQ staff will inform the Company that it has been granted an additional 180 calendar day compliance period.
If the Company is not eligible for an additional 180-day compliance period, the NASDAQ staff will provide written notice that the Company’s securities will be subject to delisting. At that time, the Company may appeal the NASDAQ staff’s determination to delist its securities to a NASDAQ Hearings Panel. There can be no guarantee that the Company will be able to maintain its NASDAQ listing.
If the FDA lifts the partial clinical hold on proellex we could see $5+ cause that means we will get a partnership with big pharma and lots and lots of $$$$$$$
Is it true that delistment may occur after 6/26 due to inability to achieve 2.5m stockholder equity?
anyone who listens to Hiwatt is getting stupid advice just like the legacy of faulty invalid repros management.
hahahaha. repros will be delisted in short order! such stupid morons running this turd mentored by an idiot! shareholders should sue the brown goo out of Joey and his reckless management.
How low will the PPS go?
what a legecy Joey P left on this turd! 34 cents and going nothing but down. anything that had joey P's fingertips on it is going to have dog doo doo stains left on it. happy trails!
Things seem to be getting overextended for RPRX. google awesome_stock.s - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
up after hours. ...that's a first....tomorrow should be interesting
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks Sep-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is 0.7 In other words, the correlation coefficient of the other stock
Nice volume today something must be cooking !!
Getcha Popcorn Ready
News on phase III should be coming within 1.5 weeks ... interesting, for sure
ok back in heavy i added today i feel that Proellex will go on to be a $400M a year in sales for female fibroid eliminator......i say yes to phase 3 in 1/4 weeks...than $6-8...last time took a shot on RPRX it went from $8 to $16 within a week on news of phase 3 enclompehine citrate on cuban men.....